Tomi Kuusimäki1,2, Samu Kurki3, Jussi O T Sipilä1,2,4, Heli Salminen-Mankonen5, Olli Carpén3,6,7, Valtteri Kaasinen1,2. 1. Division of Clinical Neurosciences Turku University Hospital Turku Finland. 2. Department of Clinical Neurosciences University of Turku Turku Finland. 3. Auria Biobank, University of Turku and Turku University Hospital Turku Finland. 4. Siun Sote, North Karelia Central Hospital, Department of Neurology Joensuu Finland. 5. Turku Centre for Biotechnology University of Turku and Åbo Akademi University Turku Finland. 6. Department of Pathology University of Turku and Turku University Hospital Turku Finland. 7. Department of Pathology and Research Program for Systems Oncology University of Helsinki and Helsinki University Hospital Laboratory, Helsinki University Hospital Helsinki Finland.
Abstract
BACKGROUND: Advances in the treatment of Parkinson's disease (PD) and changes in general life expectancy may have improved survival in patients with PD. OBJECTIVE: The objective of this study was to investigate recent trends in PD mortality. METHODS: In total, 1521 patients with PD in local and national registries were followed for 11 years (2006-2016) from diagnosis until exit date or death, and the causes of death were recorded. RESULTS: The survival of men with PD improved during the follow-up period, but no change was observed in women (2-year postdiagnosis survival in men, 79.0%-86.3%, P = 0.03; 2-year postdiagnosis survival in women, 82.8%-87.5%, P = 0.42). Pneumonia was the most common immediate cause of death. DISCUSSION: The survival of men with PD has improved in Finland without a similar change in women. Because changes in treatment likely affect both sexes similarly, the results may reflect the decreasing sex gap in life expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD.
BACKGROUND: Advances in the treatment of Parkinson's disease (PD) and changes in general life expectancy may have improved survival in patients with PD. OBJECTIVE: The objective of this study was to investigate recent trends in PD mortality. METHODS: In total, 1521 patients with PD in local and national registries were followed for 11 years (2006-2016) from diagnosis until exit date or death, and the causes of death were recorded. RESULTS: The survival of men with PD improved during the follow-up period, but no change was observed in women (2-year postdiagnosis survival in men, 79.0%-86.3%, P = 0.03; 2-year postdiagnosis survival in women, 82.8%-87.5%, P = 0.42). Pneumonia was the most common immediate cause of death. DISCUSSION: The survival of men with PD has improved in Finland without a similar change in women. Because changes in treatment likely affect both sexes similarly, the results may reflect the decreasing sex gap in life expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD.
Authors: C H Adler; K D Sethi; R A Hauser; T L Davis; J P Hammerstad; J Bertoni; R L Taylor; J Sanchez-Ramos; C F O'Brien Journal: Neurology Date: 1997-08 Impact factor: 9.910
Authors: Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: Simone Veronese; G Gallo; A Valle; C Cugno; A Chiò; A Calvo; P Cavalla; M Zibetti; C Rivoiro; D J Oliver Journal: BMJ Support Palliat Care Date: 2015-07-16 Impact factor: 3.568
Authors: C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini Journal: Lancet Neurol Date: 2013-12-20 Impact factor: 44.182